A recent study published in Clinical Pharmacology & Therapeutics reinforced the value of pharmacogenetic testing by showing how genetic variations influence drug safety and efficacy. These findings align with MEDLYTx, our flagship pharmacogenomic testing service, harnessing Next-Generation Sequencing (NGS) technology to evaluate over 250 drug interactions. Designed for conditions like neurology, oncology, cardiovascular diseases and much more, MEDLYTx provides personalized medication recommendations that optimize treatment outcomes and reduce adverse drug reactions.
Key Findings
Prevalence of Actionable Drug Use
According to the study, 60.4% of the nationwide cohort and 49.8% of the HUS (Helsinki University Hospital) cohort patients were prescribed actionable drugs.
Ibuprofen, codeine, warfarin, and simvastatin were predominantly used, alongside other actionable drugs such as proton pump inhibitors, antiemetics, and antithrombotics.
All of which MEDLYTx covers in its pharmacogenomic testing services. These findings highlight the extensive use of such medications and the potential to prevent adverse drug reactions through preemptive pharmacogenomic testing.
High Frequency of Actionable Genotypes
Among the genotyped subset of the HUS cohort:
98.8% of patients carried at least one actionable genetic variant
23.3% of these patients had at least one actionable gene-drug pair
MEDLYTx addresses these needs by providing healthcare providers with lifetime access to detailed genetic reports, helping clinicians identify safe and avoidable medications for their patients.
Cost-Benefit Analysis
A cost-benefit analysis performed in the study revealed that preemptive pharmacogenetic testing could result in significant savings.These results parallel the value proposition of MEDLYTx, which aims to minimize harmful drug interactions and improve therapy outcomes by guiding safer, more effective prescribing practices based on genetic data.
At Kyvor Genomics, we are proud to lead the way in personalized healthcare with MEDLYTx, revolutionizing treatment decisions and ensuring safer, more effective patient care.